NK Cell Therapy and Other Cell Treatments Offered Privately — what the evidence actually shows

NK cell therapy is a form of adoptive cell therapy. Natural killer cells — a type of white blood cell — are taken from you, from a healthy donor, or from cord blood, multiplied in a laboratory, and given back through a drip. The intention is to add immune cells that can act on cancer without being trained first.

Natural killer cells belong to the innate immune system. Unlike T cells, they do not have to be shown a target beforehand. They patrol, and they act on cells that look abnormal or that have hidden the markers a T cell would look for. That biology is genuinely interesting, and it is why the class is being studied seriously in laboratories and in trials around the world.

NK cell therapy is also not one thing. Autologous means your own cells. Allogeneic means a healthy donor's, or cells derived from cord blood. CAR-NK means NK cells genetically engineered to carry a targeting receptor, in the way CAR-T cells are. These are different processes with different risks, and no honest page describes them as a single treatment.

It helps to separate all of this from the immunotherapy that already has approvals. Checkpoint inhibitors, BCG into the bladder and the older cytokines are all immunotherapy, and all are prescribed in Indian cancer care today — Interferon and Interleukin: The Older Immunotherapies covers the oldest of them. NK cell therapy sits in a different category: a cell product, still under investigation.

This page describes practices, not businesses. It sets out how these offers are structured and what to check. It does not name any clinic, practitioner or product, and nothing here is a recommendation for or against a particular centre.

Early. As of August 2026 the human evidence is mostly early-phase trials — small numbers of patients, testing safety and dose, largely in blood cancers. No NK cell therapy is established as standard treatment for any cancer. Anyone quoting you a success rate for it is quoting something the published evidence does not support.

Early-phase evidence answers a narrow question: is this safe enough, at what dose, and does anything measurable happen. It does not answer the question families actually have, which is whether it will help. That needs larger randomised trials, and for NK cell products those are still running or still to come. NCCN, ASCO and ESMO do not list NK cell therapy as a standard treatment option in their patient-facing material as of August 2026.

This is a real gap, not a polite hedge. It is possible to say the science is promising and that the evidence is immature, and for both to be true. What is not honest is converting an early trial into a price list.

Positions above reflect NCCN, ASCO and ESMO patient-education material and Indian regulatory status as of August 2026, and describe categories of treatment rather than products. Approval status changes over time; your treating team and the CDSCO record are the current source.

For contrast, in the same blood cancers there are newer treatments that did complete the full evidence path before reaching patients — Bispecific Antibodies for Blood Cancers describes one such class and what its approvals actually cover.

Not as a routine cancer treatment. As of August 2026 there is no NK cell therapy we can confirm holds a CDSCO approval as standard cancer care in India. If a centre tells you otherwise, that is checkable: ask to see the approval, and ask which cancer and which stage it covers.

Three sentences settle most of these conversations. Approved abroad is not approved here. Approved for research is not approved for treatment. Approved for another cancer is not approved for yours.

There is a legitimate way to receive an investigational cell therapy in India, and it is a registered clinical trial. A trial has a written protocol, an ethics committee, a registration number with the Clinical Trials Registry – India that you can look up yourself, a participant information sheet, and a consent process. It also has someone accountable if something goes wrong. If none of that paperwork exists, what is being offered is not a trial, whatever it is called.

Trials are also not a queue anyone can simply join. They recruit for defined diseases at defined stages, at named sites, and eligibility is decided by the study team. This page cannot enrol anyone and does not try to; it explains how the route works so you can ask about it.

Eight questions, all about paperwork rather than immunology. What is it called. Is it approved, and for which cancer. Is it a registered trial. Who is responsible if you react badly. What are you being asked to stop. What does it cost in total. You do not need to argue with anyone — you need answers in writing.

None of this requires you to be rude, and none of it requires you to understand immunology. Take the eight questions with you, ask them in order, and keep the answers on paper. If you would rather someone else asked them, bring the paperwork to an oncologist and let them do it.

They sit in the same category: sold ahead of the evidence. Dendritic-cell packages, ozone therapy, hyperthermia, intravenous immunity drips and stem-cell “rejuvenation” are all offered to cancer patients in India. Some are genuinely being studied. Being studied is not the same as being proven, and none of these is standard cancer treatment here.

• Dendritic-cell vaccine packages — a real research field that has been sold retail for years ahead of its evidence. The eight questions above apply unchanged, and the answers usually run out at question two.
• Ozone therapy and hyperthermia — marketed as “immune activating” and often bundled with the rest. Ozone, Hyperthermia and ‘Immune’ Therapies Sold to Cancer Patients sets out what the published evidence does and does not show.
• Intravenous “immunity drips” — high-dose vitamin and antioxidant infusions. They are not cancer treatment, they are not free of risk, and some can interfere with treatment you are already receiving.
• Stem-cell “immune rejuvenation” — outside the defined transplant setting for certain blood cancers, stem-cell use in cancer is investigational under India's national stem-cell research guidance. It is a research activity, not a service to be purchased.
• Preparations from traditional systems — nobody here is asking a family to abandon Ayurveda, homeopathy or a household practice. The ask is narrower: tell the treating team what is being taken. Several preparations affect liver readings, and liver readings are one of the main things an immunotherapy team watches.

• Ozone, Hyperthermia and ‘Immune’ Therapies Sold to Cancer Patients — the same due-diligence lens applied to the therapies most often bundled with a cell-therapy offer.
• Bispecific Antibodies for Blood Cancers — what a treatment class looks like once it has completed the evidence path, and what its approvals actually cover.
• Interferon and Interleukin: The Older Immunotherapies — the immune treatments that have been in Indian cancer care for decades, and where they still have a place.
• Immunotherapy at CION Cancer Clinics — the hub page: biomarker testing, what is actually approved, day-care administration and side-effect monitoring in one place.

This page is general information written from a scientific standpoint. It is not a treatment recommendation, not a substitute for consultation, and not an offer of any treatment described on it. No clinic, practitioner or product is named or endorsed here, and no claim is made that any therapy discussed is effective. Regulatory and evidence positions are stated as of August 2026 and change over time. CION does not provide CAR-T, NK cell therapy or any other cell therapy; the immunotherapy CION does provide is administered as day care at CION centres, and response-assessment PET-CT is coordinated at partner imaging centres. Only your oncologist, reviewing your complete case, can say what applies to you.

A second opinion costs you nothing

Families are often asked to decide in a day. You are allowed to take the offer away, show it to an oncologist, and come back.